Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Neuroscientific Biopharmaceuticals EV-to-OCF?
Neuroscientific BiopharmaceuticalsASX:NSB EV-to-OCF is -13.66 as of Aug. 25, 2026. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, Neuroscientific Biopharmaceuticals ranks better than 75.44% on this metric.
ASX:NSB'
s EV-to-OCF Range Over the Past 10 Years
Min: -13.66 Med: 0 Max: -13.66
Current: -13.66
During the past 7 years, the highest EV-to-OCF of Neuroscientific Biopharmaceuticals was -13.66. The lowest was -13.66. And the median was .
ASX:NSB's EV-to-OCF is ranked better than 75.44% of 1409
companies
in the Biotechnology industry
Industry Median: -3.63
vs ASX:NSB: -13.66
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neuroscientific Biopharmaceuticals's PE Ratio (TTM) for today is calculated as:
Neuroscientific Biopharmaceuticals's share price for today is A$0.065.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuroscientific Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Neuroscientific Biopharmaceuticals EV-to-OCF Related Terms
Neuroscientific Biopharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Neuroscientific Biopharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuroscientific Biopharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuroscientific Biopharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Neuroscientific Biopharmaceuticals's EV-to-OCF falls into.
Neuroscientific Biopharmaceuticals's current Enterprise Value is A$18.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuroscientific Biopharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuroscientific Biopharmaceuticals (ASX:NSB) has a EV-to-OCF of -13.66 as of Aug. 25, 2026. According to the industry distribution chart, Neuroscientific Biopharmaceuticals ranks #346 out of 1409 companies in the Biotechnology industry, placing it in the top 24.6%.
Is Neuroscientific Biopharmaceuticals' EV-to-OCF too high?
Neuroscientific Biopharmaceuticals' current EV-to-OCF is -13.66. Based on the distribution chart, Neuroscientific Biopharmaceuticals ranks #346 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Neuroscientific Biopharmaceuticals' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuroscientific Biopharmaceuticals ranks #346 out of 1409 companies for EV-to-OCF. This places Neuroscientific Biopharmaceuticals in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Neuroscientific Biopharmaceuticals's current EV-to-OCF is -13.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuroscientific Biopharmaceuticals stock overvalued right now?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a current EV-to-OCF of -13.66. The current EV-to-OCF is -13.66. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Neuroscientific Biopharmaceuticals (ASX:NSB), the current EV-to-OCF is -13.66 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and treatments for neurodegenerative diseases through preclinical studies of patented technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NSB has been successfully added to your 
